You are here

ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer

Last updated on February 20, 2019

FOR MORE INFORMATION
Study Location
University of Alabama at Birmingham
Birmingham, Alabama, 35233 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Non-Small Cell Lung Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Evidence of pathologically confirmed, advanced NSCLC (with known histology).

- Prior treatment with at least one and no more than two systemic therapy regimens (at
least one must be standard chemotherapy for advanced NSCLC).

- Adequate tissue sample must be submitted prior to randomization for tumor biomarker
analyses.

- Adequate renal, hematologic, liver function.

- ECOG PS of 0-2.

- Radiologically measurable disease.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Small cell histology.

- Symptomatic brain mets or known leptomeningeal mets.

- Prior therapy with agent known or proposed to be active by action on EGFR tyrosine
kinase or other HER family proteins.

- Uncontrolled medical disorders.

NCT01360554
Pfizer
Completed
ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Non-Small Cell Lung Cancer ALK-positive, Non-Small Cell Lung Cancer c-Met Dependent, Non-Small Cell Lung Cancer ROS Marker Positive, Systemic Anaplastic Large-Cell Lymphoma, Advanced Malignancies Except Leukemia
NCT00585195
All Genders
18+
Years
Multiple Sites
NSCLC (Non-small Cell Lung Cancer)
NCT01639001
All Genders
18+
Years
Multiple Sites
Non-small Cell Lung Cancer
NCT01597258
All Genders

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now